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Abstract 
Objective: To describe cases of dengue virus (DENV) concurrent infections in patients from both local and interna-
tional traveler visiting Bali, Indonesia.
Results: During a hospital-based study, 260 patients (from 161 local and 99 international traveler patients) were 
recruited. Among them, 190 were positive by DENV RT-PCR in which eight patients (five local and three international 
travelers) detected as having concurrent infections by two different DENV serotypes. Among the eight patients, the 
common dengue symptoms diagnosed were fever, headache, and myalgia. Six cases (75%) were diagnosed with 
dengue fever (DF) while two cases (25%) manifested with bleeding and were diagnosed with dengue hemorrhagic 
fever (DHF) grade 1. The DENVs concurrent infections involved all four DENV serotypes known to be circulating in Bali. 
Although cases of DENV concurrent infections have been implicated with severe manifestation, we observed that 
most of concurrent infections cases in our study were of mild clinical manifestation, that may be related to the chang-
ing of DENV serotype predominance which is occurring in Bali, Indonesia.
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Introduction
The dengue disease, caused by the etiological agent 
dengue virus (DENV) has been considered as the most 
important arboviral infection in the world, with signifi-
cant burden [1]. All four serotypes of DENV (DENV-1, 
-2, -3, and -4), members of the Flaviviridae family, may 
induce long-lived serotype-specific immunity and only 
confers short-lived cross-immunity [2]. Clinical mani-
festations of DENV infection vary from asymptomatic, 
mild dengue fever (DF), to the more severe dengue hem-
orrhagic fever (DHF) and life-threatening dengue shock 
syndrome (DSS), for particular people [3–5]. Risk factors 
for severe dengue are young age, female sex, high body-
mass index, virus strain, and genetic variants [6–8].
All four DENV serotypes were found to circulate in 
Asia, Africa and America with co-circulation of multiple 
DENV serotypes reported [9]. Co-circulation of DENV 
serotypes increases the risk of concurrent infections, a 
phenomenon best observed in epidemics [10, 11]. It has 
been reported that the occurrence of concurrent infec-
tions was ranging from 5% to as high as 50% [11].
Conflicting outcomes were reported in which concur-
rent infections of DENV serotypes may lead to mild or 
severe dengue manifestation [11–15]. The concurrent 
infections of DENV-serotypes in Indonesia has been 
reported, including in Bali [16] which has been known as 
a famous tourist destination both local and international. 
The hyperendemicity of DENV in Bali may affect both 
local people and international travelers [17].
In this report, we present cases of DENV concurrent 
infections in local Balinese and international travelers 
admitted to tertiary hospitals in Bali. The clinical mani-
festation characteristics related to cases of DENV con-
current infections were sought and assessed together 
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travelers visiting Bali, commenced in 2015–2017 [16, 17]. 
Samples were collected from patients seeking medica-
tion to three tertiary hospitals in Bali, namely RS Kasih 
Ibu, Denpasar; RS Sanjiwani, Gianyar; and RS Wangaya, 
Denpasar. Serum samples were obtained from patients’ 
blood during acute phase from day 0 up to day 5 of fever 
onset and convalescence sera were taken on patients’ 
hospital discharge day. All patients were adults with age 
of > 14 years old. The grading of dengue clinical manifes-
tation was implementing the WHO-SEARO guidelines 
[8] and diagnosis of dengue hemorrhagic fever (DHF) was 
based on the evidence of plasma leakage which includes 
the hematocrit (HCT) level increase or the findings of 
pleural effusion or ascites on physical examination. The 
assessment of plasma leakage evidence was performed 
based on > 20% drop in HCT following volume replace-
ment treatment compared to baseline [8], i.e. HCT level 
differences of more than 20% between the highest HCT 
level recorded during the phase of illness and level during 
convalescence. Thrombocytopenia was defined as a rapid 
decline of platelet with platelet count of < 100 × 109/L.
Serology testing, DENV detection, serotyping, 
and genotyping
The anti-DENV IgM and IgG serology detection was 
done using Panbio Dengue Duo IgM/IgG ELISA kit 
(Alere, Brisbane, Australia) to determine the infection 
status as primary or secondary infection, as described 
previously [18]. Dengue was confirmed through DENV 
NS1 antigen detection using the SD Bioline NS1 Rapid 
Test (Alere). The DENV RNA was extracted from 
serum sample using QIAamp Viral RNA Mini kit (Qia-
gen, Hilden, Germany) according to the manufactur-
er’s instructions, and used as template in simultaneous 
DENV detection and serotyping by real-time RT-PCR 
using Simplexa Dengue (DiaSorin, Cypress, CA, USA), 
as described elsewhere [19]. The positively detected 
DENV nucleic acid in samples was reported as the result-
ing DENV serotype and its Ct value correspond to the 
semi-quantitative measurement of viral titer where lower 
Ct value correlate with higher viral titer and vice versa. 
Genotype determination was performed using Sanger 
capillary sequencing of the DENV envelope (E) gene, as 
described elsewhere [20].
Results
Clinical and laboratory examinations of the concurrent 
infections cases
A total of 260 samples were collected during the study. 
The total samples comprise of 161 local and 99 inter-
national traveler patients. Among them, eight patients 
were of DENV concurrent infections as simultaneously 
detected and serotyped using real-time RT-PCR. The 
clinical and laboratory examinations data of patients 
with DENV concurrent infections were summarized in 
Table 1.
All cases presented with fever and the majority of 
patients had headache, myalgia, and vomiting. There was 
no serious bleeding observed in cases, except for pete-
chiae and gum bleeding. Likewise, there was no fluid 
accumulation or shock observed in all cases. The level of 
liver enzymes and albumin were gradually reached the 
relatively normal level. Laboratory results showed no 
signs of leukocytosis in majority of the cases with rela-
tively normal hemoglobin levels. Thrombocytopenia was 
observed only in case 2, 3, 4, and 6.
DENV infection status, serotypes, and genotypes
In term of DENV infection status as inferred from serol-
ogy results, most of the cases were of secondary infec-
tion. We observed that secondary infection was observed 
in all local patients, while all international travelers were 
characterized as of primary infection (Table 1). Serology 
detection revealed the IgM positivity of 87.5% among 
concurrent infections cases.
From 260 collected samples, 190 were successfully 
determined for their infecting DENV serotype. Among 
them, 182 samples were of mono-infection while 8 sam-
ples were of concurrent infections of two different DENV 
serotypes. The DENV concurrent infections involved all 
four DENV serotypes with most of the cases involving 
DENV-1 (Table 1). Three cases were of DENV-1 and -2 
concurrent infections while two cases involving DENV-1 
and -3. The remaining two cases involved DENV-2 and 
-4 and one case serotyped as having DENV-3 and -4. 
In term of the Ct values of each DENV serotype meas-
ured using real-time RT-PCR, majority of cases showed 
relatively equal Ct values although there was presence of 
higher Ct value in one serotype than the other serotype 
of the concurrent infections (Table 1).
Genotype determination was performed to one case 
of concurrent infections (Case 8) where both of the 
DENV-2 and -4 serotypes were successfully sequenced 
(data not shown). Utilizing Twiddy, et al. classification for 
DENV-2 [21], the DENV-2 isolate of case 8 was grouped 
into the Cosmopolitan genotype. The other DENV-4 
isolate of case 8 was classified into the Genotype II of 
DENV-4 grouping based on Lanciotti, et al. classification 
[22].
Data comparison between DENV mono‑infection 
and concurrent infections cases
We performed a comparison between clinical and labora-
tory data from cases with mono-infection and concurrent 
infections (Table 2). However, the small number of con-
current infections cases was limiting statistical analysis. 
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Despite the gender proportion, other clinical and labora-
tory experiment data showed similar features, including 
the infection status where the majority of mono-infec-
tion and concurrent infection cases were of secondary 
infection. In term of severity, concurrent infection cases 
showed relatively milder manifestations than cases of 
mono-infection.
Discussion
The circulation of multiple DENV serotypes within the 
same geographical area increases the risk of concurrent 
infections that mostly occurs during an epidemic [10, 
11]. The first case of DENV concurrent infections was 
reported from a study in Puerto Rico in 1982 [14]. His-
torically, DENV concurrent infections cases has been 
reported in samples isolated in Indonesia since 1976 [15]. 
The recent surveillance reports from Indonesia reported 
the DENV concurrent infections occurrence ranged from 
1.6 to 29.0% [16, 18, 20, 23, 24].
It has been proposed that DENV hyper-endemicity, 
which leads to concurrent infections, was the contribut-
ing factor for severe dengue [12]. However, in this case 
report, the occurrence of DENV concurrent infections 
in patients was related to relatively mild clinical mani-
festation with no serious bleeding, fluid accumulation 
or shock observed (Table  1). The clinical assessment 
results were supported with laboratory examination data 
in which no signs of leukocytosis, one of the indicators 
of severe dengue [25], was detected. However, signs of 
thrombocytopenia were observed in some of the patients 
(Table 1). Two cases were clinically graded as DHF grade 
Table 1 Demographic and clinical variables among concurrent infections cases
+, positive; −, negative; DF, dengue fever; DHF, dengue hemorrhagic fever; WBC, white blood cell; HCT, hematocrit; PLT, platelet; AST, aspartate aminotransaminase; 
ALT, alanine transaminase; DVT, deep vein thrombosis; N/A, not applicable due to insufficient sample volume
a Determined using Simplexa Dengue qRT-PCR
Variable Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Demography and clinical manifestations
Age range, years old 20–30 20–30 30–40 40–50 30–40 40–50 50–60 50–60
Race/nationality Balinese Balinese Balinese Balinese Balinese French French Austrian
Gender Male Female Male Male Male Female Male Male
Fever day 3 3 3 5 2 3 3 3
Headache + + + – – + + +
Arthralgia + + + + – + – +
Myalgia + + + + – + – +
Vomiting + + – – – + – –
Bleeding manifesta-
tion
+ (Petechiae) – – – – + (Gum) – –
Shock – – – – – – – –
Plasma leakage – + – + – – – –
Comorbidity – – – – – – + (DVT) –
Laboratory examinations data
Nadir WBC (× 10 µg/
µL)
4.10 3.00 2.70 2.90 2.06 1.16 2.84 1.13
HCT difference (%) 12.0 21.4 9.9 21 11.9 6.1 7.4 11.1
Nadir PLT (× 109/L) 122 91 16 56 114 56 117 113
AST (U/L) 34 167 N/A 164 N/A 24 59 40
ALT (U/L) 23 190 N/A 168 N/A 14 42 36
Albumin (g/L) 3.8 3.0 N/A 3.4 N/A N/A 3.8 3.8
DENV NS1 + + + + + + + +
Dengue IgM + + – + + + + +
Dengue IgG + + + + + – – –
Infection status Secondary Secondary Secondary Secondary Secondary Primary Primary Primary
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I due to the HCT levels difference of more than 20% 
between acute and convalescence sera (Table 1).
The majority of concurrent infections cases were of 
secondary infection as determined by serology and all 
of them are patients from local Balinese. It has been 
reported that the number of secondary infection in 
adults are higher, especially in an endemic area like Bali 
with prolonged exposure to dengue infection in the 
past [16]. Interestingly, cases from international trave-
lers were of primary infection with only anti-DENV 
IgM antibody detected (Table  1). Looking into their 
history, the travelers stated that they have never been 
contracted to dengue in the past. Moreover, the trave-
lers were coming from countries where dengue is not 
endemic.
The DENV serotypes involved in concurrent infec-
tions were mostly involved DENV-1 and dominated by 
mix of DENV-1 and -2, followed by DENV-1 and -3, 
DENV-2 and -4, and DENV-3 and -4. In term of clini-
cal manifestation caused by DENV concurrent infec-
tions, our findings are in line with previous reports 
from Brazil which observed mild dengue manifesta-
tion caused by concurrent infections of DENV-1 and 
DENV-2 [26, 27] and DENV-3 and DENV-4 [28]. The 
involvement of DENV-1 in majority of the concurrent 
infections cases was also observed in previous reports 
of concurrent infections in Semarang [20] and Sura-
baya [18]. Reports have been proposing the phenomena 
of serotype replacement in places in Indonesia where 
DENV-1 has becoming the predominant serotype [18, 
20, 23, 24, 29]. Our previous dengue surveillance in 
local Balinese observed the rise of DENV-1 infection as 
the second most common serotype detected in patients 
[16]. It may happen that this cyclical serotype predomi-
nance is currently occurring in Bali, the condition that 
needs to be continuously monitored. The relationship 
of DENV-1 predominance with mild dengue manifesta-
tion has also been observed in a surveillance study in 
Jambi, Sumatra [23].
Previous studies have correlated the higher viremia 
level with severe dengue clinical manifestation in DENV 
concurrent infections [12, 30]. In a case report, sig-
nificantly higher titer of DENV-3 over DENV-2 was 
recorded in which may suggest the better replication rate 
of the former compared to the latter [12]. However, in 
this study, only one DHF case was reported to have sig-
nificantly higher viral titer (as of Ct value) of DENV-1 
over DENV-2. In other DHF case, similar Ct values were 
recorded. Moreover, we did not observe the correlation 
of higher DENV serotype titer with severe clinical mani-
festation in the majority of cases (Table  1). It has also 
been reported that the host (secondary infection status) 
and viral factors (viral load titer) influenced the clinical 
phenotype of severe dengue manifestations [31]. Our 
data may suggest that there may be other factors influ-
encing clinical manifestation, especially in concurrent 
infections cases.
Looking deeper into the genotypes of the DENV sero-
types from the concurrent infections cases, both geno-
types of the infecting DENV serotypes were successfully 
obtained for one case. The DENV-2 isolate of case 8 were 
grouped into Cosmopolitan genotype and the DENV-4 
classified as Genotype II. These classifications were still 
correspond to the genotype data of DENV in Bali [16], 
reflecting the endemicity of DENV and occurrence of 
active virus transmission in the island.
In term of comparison between concurrent infection 
samples and other samples detected as having only single 
Table 2 Demography, clinical, and  laboratory data 
comparison between  mono-infection and  concurrent 
infections cases during dengue surveillance in Bali
DF, dengue fever; DHF, dengue hemorrhagic fever; WBC, white blood cell; HCT, 
hematocrit; PLT, platelet
Variable Mono-infection 




Demography and clinical manifestations
Age, median year (range) 28 (14–75) 42 (25–53)
Male, N (%) 80 (44.0) 7 (87.5)
Female, N (%) 102 (56.0) 1 (12.5)
Fever day, days ± SD 3.3 ± 0.83 2.0 ± 0.93
Headache 139 (76.4) 7 (87.5)
Arthralgia 101 (55.5) 6 (75.0)
Myalgia 122 (67.0) 6 (75.0)
Vomiting 92 (50.5) 2 (25.0
Bleeding 46 (25.3) 2 (25.0)
Plasma leakage 0 (0.0) 0 (0.0)
Shock 0 (0.0) 0 (0.0)
Laboratory examinations data
Nadir WBC (× 10 µg/µL), median 
(range)
2.1 (0.48–6.4) 2.77 (1.16–4.1)
HCT difference (%), median 
(range)
13.1 (2.43–68.9) 11.5 (6.1–21.4)
Nadir PLT (× 109/L), median 
(range)
43 (6–194) 102 (16–122)
DENV NS1 test positivity, N (%) 173 (95.1) 8 (100.0)
Dengue IgM positivity, N (%) 123 (67.6) 7 (87.5)
Dengue IgG positivity, N (%) 142 (78.0) 5 (62.5)
Dengue severity
DF, N (%) 110 (60.4) 6 (75.0)
DHF grade 1, N (%) 42 (23.1) 2 (25.0)
DHF grade 2, N (%) 26 (14.3) 0 (0.0)
DHF grade 3, N (%) 4 (2.2) 0 (0.0)
DHF grade 4, N (%) 0 (0.0) 0 (0.0)
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or mono infection, we observed a relatively similar clini-
cal and laboratory profiles where relatively milder mani-
festations were observed in concurrent infections cases 
(Table 2). Nevertheless, both groups reflected mild den-
gue manifestations where the majority of them were of 
DF manifestation, with only a small proportion develop-
ing DHF [16, 17]. Although it has been reported that co-
infected patients are skewed towards more severe clinical 
manifestations compared to mono-infected patients [11], 
in this research note, our results suggested that patients 
having concurrent infections of DENV were not prone to 
severe disease.
In conclusions, we report cases of DENV concurrent 
infections among local Balinese and international travel-
ers. We highlighted that the concurrent infections were 
not directly associated with severe dengue.
Limitations
The small number of concurrent infections samples 
described may not be sufficient to describe the clinical 
manifestation related to DENV concurrent infections. 
Hence, this finding needs to be supported with bigger 
and nation-wide surveillance data.
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